Corneal endothelial rejection after penetrating keratoplasty treated with intravenous and topic corticosteroid. One year follow up

dc.creatorAbe, RY
dc.creatorFreire, LMD
dc.creatorCastro, RS
dc.creatorLira, RPC
dc.creatorArieta, CEL
dc.date2013
dc.dateJAN-FEB
dc.date2014-07-30T14:02:38Z
dc.date2015-11-26T17:25:43Z
dc.date2014-07-30T14:02:38Z
dc.date2015-11-26T17:25:43Z
dc.date.accessioned2018-03-29T00:12:56Z
dc.date.available2018-03-29T00:12:56Z
dc.identifierRevista Brasileira De Oftalmologia. Soc Brasileira Oftalmologia, v. 72, n. 1, n. 42, n. 45, 2013.
dc.identifier0034-7280
dc.identifierWOS:000315963400010
dc.identifierhttp://www.repositorio.unicamp.br/jspui/handle/REPOSIP/57221
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/57221
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1284383
dc.descriptionObjective: To analyze the recovery of visual acuity (VA) and graft survival after first episode of endothelial rejection in penetrating keratoplasty (PKP) treated with intravenous (IV) and topic corticosteroid. Methods: Interventional, prospective, non-comparative case series study evolving 32 PKP patients in one year follow up, who presented first episode of corneal endothelial rejection. The patients were submitted to 500 mg IV injection of methylprednisolone in association with topical prednisolone. Main outcome measures included VA recovery and corneal edema regression. Second outcome included new rejections and graft failure. Multivariate analysis techniques were used to estimate rates of graft outcome events and the impact of risk factors. Results: A total of 32 eyes from 32 patients (13 male and 19 female) were included in the study. The mean VA (in number of letters) before rejection was 48 (22 to 88 letters). Patients treated within 7 days or less of initial symptoms had better VA recovery, corneal edema regression and less graft failure (p<0.001). Patients with previous ocular surgery had worse VA recovery and more graft failure (p<0.047). Conclusion: The association between the other risk factors and the outcomes did not reach statistical significance in the multivariate model because of the small numbers of patients. Methylprednisolone in association with topical prednisolone is an alternative treatment for graft rejection. Our study showed that patients treated within 7 days of symptoms and no previous anterior segment surgery had better visual outcome and graft survival after treatment.
dc.description72
dc.description1
dc.description42
dc.description45
dc.languageen
dc.publisherSoc Brasileira Oftalmologia
dc.publisherRio De Janeiro
dc.publisherBrasil
dc.relationRevista Brasileira De Oftalmologia
dc.relationRev. Bras. Oftalmol.
dc.rightsaberto
dc.sourceWeb of Science
dc.subjectKeratoplasty, penetrating
dc.subjectGraft rejection
dc.subjectAdrenal cortex hormones
dc.subjectRisk factors
dc.subjectMethylprednisolone/administration & dosage Methylprednisolone/therapeutic use
dc.subjectTreatment outcome
dc.subjectGraft-rejection
dc.subjectPulse Therapy
dc.subjectMethylprednisolone
dc.titleCorneal endothelial rejection after penetrating keratoplasty treated with intravenous and topic corticosteroid. One year follow up
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución